[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-628484-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-628484-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","nano-based-drug-delivery-systems-for-the-treatment-of-non-infectious-uveitis","Nano-based Drug Delivery Systems for the Treatment of Non-infectious Uveitis","","Non-infectious uveitis (NIU) is a major cause of global visual impairment, yet current therapies rely on corticosteroids, immunosuppressants, and biologics that are limited by ocular anatomical barriers and adverse drug side effects. This review evaluates therapeutic challenges and describes nano-based intraocular drug delivery systems designed to enhance bioavailability, support targeted delivery, enable sustained release, and reduce toxicity. It concludes that nanotechnology-driven delivery is a promising strategy to meet unmet clinical needs in NIU treatment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/nano-based-drug-delivery-systems-for-the-treatment-of-non-infectious-uveitis/628484/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/nano-based-drug-delivery-systems-for-the-treatment-of-non-infectious-uveitis/628484.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-09","2026-10-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What makes non-infectious uveitis treatment challenging?","Question",{"text":63,"@type":64},"NIU therapies are constrained by ocular anatomical barriers and significant adverse side effects, which limit drug delivery and effectiveness.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why are nano-based drug delivery systems considered promising for NIU?",{"text":68,"@type":64},"Nano-based systems can improve targeting and bioavailability, provide sustained drug release, reduce side effects, and overcome limitations of conventional ocular delivery methods.",{"name":70,"@type":61,"acceptedAnswer":71},"What types of nano-based delivery systems are highlighted in the review?",{"text":72,"@type":64},"The review describes liposomes, dendrimers, hydrogels, nanoparticles, nanomicelles, nanosuspensions, and nanoemulsions as potential intraocular drug delivery approaches for NIU.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},628484,1792697801,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Advances in Ophthalmology Practice and Research 5 (2025) 124–134  \nContents lists available at ScienceDirect  \nAdvances in Ophthalmology Practice and Research  \njournal [homepage:](homepage: www.journals.elsevier.com/advances-in-ophthalmology-practice-and-research)[ www.journals.elsevier.com/advances-in-ophthalmology-practice-and-research](homepage: www.journals.elsevier.com/advances-in-ophthalmology-practice-and-research)  \nReview  \nNano-based drug delivery systems for the treatment of non-infectious uveitis Xingdi Wu a, b, 1, Mengyuan Hu a, b, 1, Yilu Cai c, Fan Jia d, e, Yang Ye a, b, Naiji Yu a, b, Min Chen a, b, **, Kaijun Wang a, b, *  \na Department of Ophthalmology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China b Zhejiang Provincial Key Lab of Ophthalmology, Hangzhou, China  \nc Zhejiang University School of Medicine, Hangzhou, China  \nd MOE Key Laboratory of Macromolecule Synthesis and Functionalization of Ministry of Education, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, China  \ne Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China  \n| A R T I C L E I N F O |  | A B S T R A C T |\n| --- | --- | --- |\n| Keywords:\u003Cbr>Non-infectious uveitis Ocular barriers Drug delivery systems Nanocarriers Pharmacotherapy |  | Background: Uveitis is one of the most prevalent causes of global visual impairment. The current approaches to treating non-infectious uveitis (NIU) involve the utilization of corticosteroids, immunosuppressant and biologics agents. Nevertheless, the intricate ocular anatomy barriers and adverse side effects of the drugs pose significant obstacles to effective treatment outcomes.\u003Cbr>Main text: To improve drug bioavailability and therapeutic outcomes for NIU while minimize side effects, researchers are committed to developing novel nano-based drug delivery systems (DDS), which have the capacity to achieve targeted delivery, increase bioavailability, achieve sustained release, reduce side effects and improve therapeutic effects. Thus, DDS based on nanotechnology, including liposome, dendrimer, hydrogels, nanoparticles, nanomicelles, nanosuspensions and nanoemulsions have emerged as promising alternatives to conventional ocular delivery methods for the management of NIU.\u003Cbr>Conclusions: In this review, we summarize the current therapeutic challenges faced by NIU and describe various nano-based intraocular DDS involved in the treatment of NIU. It is concluded that nano-based DDS is an appealing approach to addressing the unmet needs for the treatment of NIU. |\n\n1. Introduction  \nUveitis, marked by intraocular inflammation affecting the iris, ciliary body, and choroid, manifests with symptoms such as pain, redness, photophobia, and shed tears.1 The estimated incidence of uveitis ranges from 17 to 52 cases per 100000 population. It is believed to account for 5%–20% of total blindness in the developed world and 25% in the developing world. The increased social morbidity of uveitis is most common in working-age adults (aged 20–59 years).2,3 Uveitis can be categorized based on the anatomical site of inflammation as anterior, intermediate, or posterior, and can also manifest as panuveitis, involving inflammation across all 3 components of the uvea.4 Additionally, uveitisis also classified by its etiology, such as infectious causes, non-infectious origins, and masquerade syndromes.5 This review specifically focuses on  \nnon-infectious uveitis (NIU). Idiopathic cases, accounting for 35%–57% of uveitis cases, cannot be classified within specific ocular syndromes because of the absence of associated systemic diseases.6 The etiology of NIU remains incompletely understood, which requires further exploration of its inflammatory mechanisms to alleviate ocular inflammation and improve treatment effectiveness. Despite the","cbCaipK23pB4drcz","https://ap.wps.com/l/cbCaipK23pB4drcz","pdf",1142237,11,"English","# Introduction\n# Background and therapeutic challenges\n# Nano-based drug delivery systems for NIU\n# Conclusions","[{\"question\":\"What makes non-infectious uveitis treatment challenging?\",\"answer\":\"NIU therapies are constrained by ocular anatomical barriers and significant adverse side effects, which limit drug delivery and effectiveness.\"},{\"question\":\"Why are nano-based drug delivery systems considered promising for NIU?\",\"answer\":\"Nano-based systems can improve targeting and bioavailability, provide sustained drug release, reduce side effects, and overcome limitations of conventional ocular delivery methods.\"},{\"question\":\"What types of nano-based delivery systems are highlighted in the review?\",\"answer\":\"The review describes liposomes, dendrimers, hydrogels, nanoparticles, nanomicelles, nanosuspensions, and nanoemulsions as potential intraocular drug delivery approaches for NIU.\"}]","Nano-based Drug Delivery Systems for the Treatment of Non-infectious Uveitis | PDF",1792616753,28]